- Active, not recruiting
NCT02886065: Phase 1 - PVX-410, a Cancer Vaccine, & Citarinostat +/- Lenalidomide for Smoldering MM
Updated: Feb 10
NCT02886065: Phase 1 - PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM
A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering Multiple Myeloma
This research study is studying a targeted therapy as a possible treatment for Smoldering Multiple Myeloma.
The following intervention will be involved in this study:
Lenalidomide
Citarinostat (CC-96241)
PVX-410
Sponsor
Massachusetts General Hospital
Collaborators
ClinicalTrials.gov Identifier: NCT02886065
Official Title: A Phase 1b Study of PVX-410, a Multi-Peptide Cancer Vaccine, and Citarinostat (CC-96241), a Histone Deacetylase Inhibitor (HDAC) With and Without Lenalidomide for Patients With Smoldering Multiple Myeloma
First Posted : September 1, 2016
Click here for details on ClinicalTrials.gov
Drug: Hiltonol
Drug: Citarinostat
Drug: Lenalidomide
Biological: PVX-410
Locations
United States, Massachusetts
United States, North Carolina
United States, Ohio